Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 30. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $850.00 price target.

John Newman’s rating is based on a combination of factors that highlight both the challenges and potential of Regeneron’s current pipeline. Despite the mixed results from the AERIFY studies on itepekimab for COPD, where one trial showed statistical significance and the other did not, Newman sees potential in Regeneron’s broader portfolio. The inconsistency in trial outcomes, potentially influenced by lower-than-expected exacerbation events due to COVID-19, has not deterred the analyst’s positive outlook.
Newman maintains a Buy rating with a price target of $850, emphasizing confidence in Regeneron’s diversified pipeline beyond the AERIFY trials. The analyst acknowledges the disappointing trial results but remains optimistic about the company’s ability to leverage its extensive research and development capabilities to drive future growth. This perspective underscores a belief in the long-term value and innovation potential inherent in Regeneron’s strategic initiatives.

In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $755.00 price target.